Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts
International Journal of Nanomedicine · 2024
DOI: 10.2147/ijn.s424045 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2024. Verfasst von Jesse Demuytere und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of GI Surgery, Ghent University Hospital, and Cancer Research Institute Ghent (CRIG), Ghent, Belgium. Hauptthemen laut MEDLINE: Ovarian Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Epithelial ovarian cancer is associated with high mortality due to diagnosis at later stages associated with peritoneal involvement. Several trials have evaluated the effect of intraperitoneal treatment. In this preclinical study, we report the efficacy, pharmacokinetics and pharmacodynamics of intraperitoneal treatment with two approved nanomolecular formulations of paclitaxel (nab-PTX and mic-PTX) in a murine ovarian cancer xenograft model.
Methods
IC50 was determined in vitro on three ovarian cancer cell lines (OVCAR-3, SK-OV-3 and SK-OV-3-Luc IP1). EOC xenografts were achieved using a modified subperitoneal implantation technique. Drug treatment was initiated 2 weeks after engraftment, and tumor volume and survival were assessed. Pharmacokinetics and drug distribution effects were assessed using UHPLC-MS/MS and MALDI imaging mass spectrometry, respectively. Pharmacodynamic effects were analyzed using immunohistochemistry and transmission electron microscopy using standard protocols.
Results
We demonstrated sub-micromolar IC50 concentrations for both formulations on three EOC cancer cell lines in vitro. Furthermore, IP administration of nab-PTX or mic-PTX lead to more than 2-fold longer survival compared to a control treatment of IP saline administration (30 days in controls, 66 days in nab-PTX treated animals, and 76 days in mic-PTX animals, respectively). We observed higher tissue uptake of drug following nab-PTX administration when compared to mic-PTX, with highest uptake after 4 hours post-treatment, and confirmed this lower uptake of mic-PTX using HPLC on digested tumor samples. Furthermore, apoptosis was not increased in tumor implants up to 24h post-treatment.
Conclusion
Intraperitoneal administration of both nab-PTX and mic-PTX results in a significant anticancer efficacy and survival benefit in a mouse OC xenograft model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of GI Surgery, Ghent University Hospital, and Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
- Department of Pathology, Ghent University Hospital, Ghent, Belgium.
- Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium.
- Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri - IRCCS, Milano, Italy.
ORCID-Profile: Jesse Demuytere, Anne Hoorens, Jo Van Dorpe
Zitieren
APA
Demuytere, J., Carlier, C., Van de Sande, L., Hoorens, A., De Clercq, K., Giordano, S., Morosi, L., Matteo, C., Zucchetti, M., Davoli, E., Van Dorpe, J., Vervaet, C., & Ceelen, W. (2024). Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s424045
Vancouver
Demuytere J, Carlier C, Van de Sande L, Hoorens A, De Clercq K, Giordano S, et al. Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts. International Journal of Nanomedicine. 2024. doi:10.2147/ijn.s424045
BibTeX
@article{Demuytere2024,
author = {Demuytere, Jesse and Carlier, Charlotte and Van de Sande, Leen and Hoorens, Anne and De Clercq, Kaat and Giordano, Silvia and Morosi, Lavinia and Matteo, Cristina and Zucchetti, Massimo and Davoli, Enrico and Van Dorpe, Jo and Vervaet, Chris and Ceelen, Wim},
title = {Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts},
journal = {International Journal of Nanomedicine},
year = {2024},
doi = {10.2147/ijn.s424045}
}
EUVIMED